PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma

MIN HYE KIM¹,2, GYUNG HYUK KO¹,2,3, JEONG HEE LEE¹,2,3, JONG SIL LEE¹,2,3, DONG CHUL KIM¹,2,3, JUNG WOOK YANG¹,2,3, HYO JUNG AN²,3,4, JI MIN NA¹ and DAE HYUN SONG²,3,4

¹Department of Pathology, Gyeongsang National University Hospital, Jinju, Republic of Korea; ²Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea; ³Gyeongsang Institute of Health Science, Jinju, Republic of Korea; ⁴Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea

Abstract. Background/Aim: Programmed death ligand-1 (PD-L1) and programmed death protein 1 (PD-1) expression levels in many tumors and their correlation with prognosis have been actively studied. However, studies on PD-1 expression and its prognostic value in clear cell renal cell carcinoma (ccRCC) are limited and controversial. In this study, we describe the expression of PD-1 and its prognostic significance and association with clinical features in patients with ccRCC. Materials and Methods: We obtained clinicopathological data from 166 patients with ccRCC who were treated at Gyeongsang National University Hospital, Jinju, Korea between January 2000 and December 2009. Tissue microarray blocks were made using representative paraffin blocks of ccRCC specimens. Two pathologists analyzed PD-L1 and PD-1 expression in both tumor and inflammatory cells. Results: PD-1 expression in tumor-infiltrating inflammatory cells was significantly correlated with unfavorable disease-free survival (DFS) (p<0.001) and disease-specific survival (DSS) (p=0.002) in the univariate analysis. A statistically significant correlation between PD-1 expression and unfavorable DFS (p=0.025) was observed in the multivariate analysis. Conclusion: PD-1 expression in tumor-infiltrating inflammatory cells serves as an independent prognostic factor for unfavorable DSS in patients with ccRCC.

This article is freely accessible online.

Correspondence to: Dr. Dae Hyun Song, Department of Pathology, Gyeongsang National University School of Medicine, 15 Jinju-daero 816 Beon-gil, Jinju 660-751, Republic of Korea. Tel: +82 552143150, Fax: +82 552143174, e-mail: golgy@hanmail.net

Key Words: Clear cell renal cell carcinoma, PD-1, immunohistochemistry, survival analysis, prognosis.
Tissue microarray. Specimens were obtained surgically and fixed overnight in neutral buffered formalin (20%). The samples were embedded in paraffin blocks. Two cores of 2-mm representative tissue were collected from each paraffin block and transplanted onto new recipient tissue microarray (TMA) blocks. Two cores were collected from the center and periphery of the tumor.

Immunohistochemical analysis. Primary antibodies against PD-L1 (1:200, E1L3N, Cell Signaling Technology, Danvers, MA, USA) and PD-1 (1:100, ab52587, Abcam, Cambridge, UK) were used to evaluate protein expression. The immunohistochemical (IHC) method is described in our previous report (20). PD-L1 scoring (SP142) was based on the percentage of PD-L1-expressing tumor cells or inflammatory cells with any intensity (21). To increase the reproducibility, we evaluated the intensity of PD-1 expression of membranous staining on tumor cells and inflammatory cells simply as negative or positive for any percentage (Figure 1).

Statistical analysis. The correlation between PD-1 expression and clinicopathological parameters was analyzed by using chi-square tests. The prognostic significance of the clinicopathological data for DFS and DSS was evaluated by Cox proportional hazards regression analysis. Survival probability was also analyzed by the Kaplan-Meier method with the log-rank test for DFS and DSS. The results were considered statistically significant when the p-value was less than 0.05. SPSS version 21.0 (IBM Corp, Armonk, NY, USA) was used for the analysis.

Results

Clinicopathological data. The clinicopathological data of patients with ccRCC (n=166) are summarized in Table I. The mean age of the patients was 59 years (range=32-84 years). There were 124 (74.7%), 12 (7.2%), 26 (15.7%), and 4 (2.4%) patients with T stage 1, 2, 3 and 4 disease, respectively. The Fuhrman nuclear grades were as follows: 30 (18.1%) were grade 1, 110 (66.3) were grade 2, 20 (12.1%) were grade 3, and 6 (3.6%) were grade 4.

PD-L1 and PD-1 expression. Of the 332 cores, 58 cores had hemosiderin pigment or artificial brown pigment, and one core was not available due to loss of the specimen. In total, 59 cores were not informative. Ultimately, 273 available cores were used for the analysis.

Of the 273 cores evaluated, 123 showed PD-1 expression in inflammatory cells and no PD-1 expression in tumor cells. No cores showed PD-L1 expression in tumor and inflammatory cells. The positive control for PD-L1 showed high expression. PD-1-positive inflammatory cells showed a membranous staining pattern.

Relationship between PD-1 expression and clinicopathological data. The relationships between PD-1 expression and clinicopathological data are shown in Table II. PD-1 expression was significantly related to male sex (p=0.046) and T stage=1 (p<0.001) but not to age (p=0.597) or Fuhrman nuclear grade (p=0.086).

PD-1 expression and survival analysis. Univariate and multivariate analyses of survival according to PD-1 expression in 273 available cores are shown in Table III. In the univariate analysis, several variables were associated with poor DFS, including age ≥60 (p=0.001), Fuhrman grades 3
1551

and 4 \( (p<0.001) \), T stage \( \geq 2 \) \( (p<0.001) \) and PD-1 expression \( (p<0.001) \). Poor DSS was also associated with age \( \geq 60 \) \( (p=0.021) \), Fuhrman grades 3 and 4 \( (p<0.001) \), T stage \( \geq 2 \) \( (p<0.001) \) and PD-1 expression \( (p=0.002) \). Moreover, multivariate analysis revealed that PD-1 expression was an independent factor for unfavorable DFS (hazard ratio=2.171; 95% confidence interval=1.103-4.275; \( p=0.025 \)).

### Discussion

Tumors are usually infiltrated by inflammatory cells. The composition of inflammatory cells and the number of each subtype differ between different tumors. These inflammatory cells interact with each other and affect the growth of tumors. In addition, these inflammatory cells can be related to a good prognosis or a poor prognosis in patients \( (22) \). Tumor microenvironments are mostly composed of tumor-infiltrating lymphocytes including CD4+ and CD8+ T cells \( (23) \). These T cells are regulated by positive and negative signals \( (24) \). Among inhibitory immune checkpoint proteins, PD-1 and PD-L1 have been actively studied, and their relationships to cancer, infectious disease, transplantation, and autoimmunity have been demonstrated \( (25-27) \). For example, a strong correlation between PD-1 and PD-L1 expression and prognosis in cancer patients has been actively demonstrated \( (8, 11, 12, 15, 16, 25) \).

Additionally, there has been significant research on PD-1 and PD-L1 and ccRCC. Usually, PD-L1 is expressed in both immune cells and tumor cells, while PD-1 is mainly expressed in tumor infiltrating lymphocytes \( (28) \). Many previous reports have also shown that PD-L1 is an independent poor prognostic factor for ccRCC \( (16, 17, 19) \). However, previous studies on the correlation between PD-1 and ccRCC are limited and controversial. Stenzel et al. \( (19) \) reported that high PD-1 expression in inflammatory cells is significantly associated with favorable cancer-specific survival. In contrast, Ueda et al. \( (16) \) reported that PD-1 expression is significantly associated with adverse outcomes in metastatic ccRCC.

Our results showed that PD-1 expression was significantly correlated with male sex and higher T stage. PD-1 expression was related to unfavorable DFS and DSS in the univariate analysis of patients with ccRCC. Moreover, PD-1 expression was related to unfavorable DFS in multivariate analysis in patients with ccRCC. Based on our results, we hypothesize that PD-1 expression inhibits T cell-mediated antitumor responses in ccRCC. This finding suggests that PD-1 pathway blockade will enhance antitumor effects in ccRCC.

Our study has limitation. Tissue microarray is a valuable technique evaluating immunohistochemical markers in tumors and used as an alternative for whole tissue sections \( (29) \). However, the possibility of intratumoral heterogeneity in biomarker expression is concerned in small tissue microarray specimen \( (30) \). There have been a few studies on PD-L1
expression and heterogeneity. Intratumoral and intertumoral heterogeneity was present in more than half of the cases (31). However, to our knowledge, there have been no studies on the intratumoral and intertumoral heterogeneity of PD-1 expression in inflammatory cells. Therefore, further studies of PD-1 expression in ccRCC with whole tumor sections are needed.

**Conclusion**

This study showed that PD-1 expression in tumor infiltrating inflammatory cells serves as an independent factor for unfavorable DSS in patients with ccRCC.

**Conflicts of Interest**

The Authors declare that they have no competing interests in relation to this study.

**Authors’ Contributions**

MHK and DHS conceived and designed this study. MHK, GHK, JHL, JSJL, DCK, JWY, JMNN, HJA and DHS collected samples, performed pathological diagnosis and analyzed the immunostained samples. MHK and DHS analyzed all the data. MHK and DHS wrote the first draft of the manuscript. GHK, JHL, JSJL, DCK, JWY, JMNN, HJA and DHS critically reviewed and corrected the manuscript. All Authors reviewed and approved the final version of the manuscript.

**References**

1 Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1): 7-34, 2019. PMID: 30620402. DOI: 10.3322/caac.21551

2 Escudier B, Porta C, Schmiderger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A and ESMO Guidelines Committee: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5): 706-720, 2019. PMID: 30788497. DOI: 10.1093/annonc/mdz056

3 Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillaux, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS and Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23(12): 2763-2771, 2005. PMID: 15837991. DOI: 10.1200/JCO.2005.07.055

4 Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS and Zincke H: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 97(7): 1663-1671, 2003. PMID: 12655523. DOI: 10.1002/cncr.11234

5 Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME and Rathmell WK: ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 66(1): 77-84, 2014. PMID: 24613583. DOI: 10.1016/j.eururo.2014.02.035

6 Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hamerlel I, Timsit MO, Tsiatis AC, Bonham M, Lebret T, Mejean A and Escudier B: A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: Development and validation studies. Lancet Oncol 16(6): 676-685, 2015. PMID: 25979595. DOI: 10.1016/S1470-2045(15)70167-1

7 Rasti A, Mehrzazm M, Madjd Z, Abolhasani M, Saeednejad Zanjani L and Asgari M: Co-expression of cancer stem cell markers OCT4 and NANOG predicts poor prognosis in renal
cell carcinomas. Sci Rep 8(1): 11739, 2018. PMID: 30082842. DOI: 10.1038/s41598-018-30168-4

8 Tamura T, Ohira M, Tanaka H, Muguruma K, Toyokawa T, Kubo N, Sakurai K, Amano R, Kimura K, Shibutani M, Maeda K and Hirakawa K: Programmed death-1 ligand-1 (pd1l) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res 35(10): 5369-5376, 2015. PMID: 26408698.

9 Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR and IASLC Pathology Committee: Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 10(7): 985-989, 2015. PMID: 26134220. DOI: 10.1097/JTO.0000000000000526

10 Kim SH, Go SI, Song DH, Park SW, Kim HR, Jang I, Kim JD, Lee JS and Lee GW: Prognostic impact of CDS and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer 120(5): 547-554, 2019. PMID: 30745585. DOI: 10.1038/s41416-019-0398-5

11 Ni X, Sun X, Wang D, Chen Y, Zhang Y, Li W, Wang L and Suo J: The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: A meta-analysis. Clin Transl Oncol 21(5): 674-686, 2019. PMID: 30392153. DOI: 10.1007/s12094-018-1970-9

12 Planes-Laine G, Rochigneux P, Bertucci F, Chrétiens AS, Viens P, Sabatier R and Gonçalves A: PD-1/PD-L1 targeting in breast cancer: The first clinical evidences are emerging, a literature review. Cancers (Basel) 11(7): 1033, 2019. PMID: 31336685. DOI: 10.3390/cancers11071033

13 Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS and Xia JC: Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Manag Res 10: 6457-6468, 2018. PMID: 30568505. DOI: 10.2147/CMAR.S181949

14 Iacovelli R, Noél F, Verri E, Renne G, Paglino C, Santoni M, Cossu Rocca M, Giglione P, Aurilio G, Cullurà D, Cascinu S and Porta C: Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol 11(2): 143-148, 2016. PMID: 26429561. DOI: 10.1007/s11523-015-0392-7

15 Xu F, Xu L, Wang Q, An G, Feng G and Liu F: Clinicopathological and prognostic value of programmed death-ligand 1 (PD-L1) in renal cell carcinoma: A meta-analysis. Int J Clin Exp Med 8(9): 14595-14603, 2015. PMID: 26628942.

16 Ueda K, Suekane S, Kurose H, Chikui K, Nakiri M, Nishihara K, Matsuo M, Kawahara A, Yano H and Igawa T: Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 36(11): 499.e9-499.e16, 2018. PMID: 30131293. DOI: 10.1016/j.urolonc.2018.07.003

17 Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH and Srougi M: PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol 10: 189, 2015. PMID: 26470780. DOI: 10.1186/s13000-015-0414-x

18 Erlmeier F, Weichert W, Schrader AJ, Autenrieth M, Hartmann A, Steffens S and Ivanyi P: Prognostic value of PD-1 and its ligands in renal cell carcinoma. Med Oncol 34(6): 99, 2017. PMID: 28432616. DOI: 10.1007/s12032-017-0961-y

19 Stenzel PJ, Schindeldecker M, Tagscherer KE, Foer sch S, Herpel E, Hohenfellner M, Hatiboglu G, Alt J, Thomas C, Haferkamp A, Roth W and Macher-Goepping er S: Prognostic and predictive value of tumor-infiltrating leukocytes and of immune checkpoint molecules PD1 and PDL1 in clear cell renal cell carcinoma. Transl Oncol 13(2): 336-345, 2020. PMID: 31881506. DOI: 10.1016/j.tranon.2019.11.002

20 Song DH, Ko GH, Lee JH, Lee JS, Lee GW, Kim HC, Yang JW, Heo RW, Roh GS, Han SY and Kim DC: Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGF-R2 expression. Oncol Lett 11(2): 998-1006, 2016. PMID: 26893682. DOI: 10.3892/ol.2015.3988

21 Teixido C, Villarino N, Reyes R and Reguart N: PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol 10: 1758835918763493, 2018. PMID: 29662547. DOI: 10.1177/1758835918763493

22 Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45): 5904-5912, 2008. PMID: 18836471. DOI: 10.1038/onc.2008.271

23 Whiteside TL: The local tumor microenvironment. In: General Principles of Tumor Immunotherapy. HL Kaufman, JD Wolchok (eds.), Springer, pp. 145-167, 2007.

24 Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5): 336-347, 2004. PMID: 15122199. DOI: 10.1038/nri1349

25 Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19(7): 813-824, 2007. PMID: 17606980. DOI: 10.1093/intimm/dxm057

26 Pondall DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4): 252-264, 2012. PMID: 22437870. DOI: 10.1038/nrc3239

27 An HJ, Ko GH, Lee JH, Lee JS, Kim DC, Yang JW, Kim MH, Kim JP, Jung EJ and Song DH: Programmed death-ligand 1 expression and its correlation with lymph node metastasis in papillary thyroid carcinoma. J Pathol Transl Med 40(4): 547-554, 2019. PMID: 30392153. DOI: 10.1016/j.jptm.2019.04.004

28 McDermott DF and Atkins MB: Immune therapy for kidney cancer: A second dawn? Semin Oncol 40(4): 492-498, 2013. PMID: 23972713. DOI: 10.1053/j.seminoncol.2013.05.008

29 Khouja MH, Baekelandt M, Sarab A, Nesland JM and Holm R: Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett 13(5): 827-831, 2015. PMID: 22966388. DOI: 10.3892/ol.2015.3000145

30 Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA and Cohen C: Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study. Appl Immunohistochem Mol Morphol 18(5): 433-441, 2010. PMID: 20485156. DOI: 10.1097/PAI.0b013e31811dddb20

31 Haragan A, Field JK, Davies MPA, Escriu C, Gruver A and Gosney JR: Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 134: 79-84, 2019. PMID: 31320000. DOI: 10.1016/j.lungcan.2019.06.005

Received March 2, 2021
Revised March 18, 2021
Accepted March 22, 2021